Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396544 | 0.82 | MEN1 (0.64) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16280011 | 0.82 | MEN1 (0.64) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL368379 | 0.81 | MEN1 (0.48) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| Hydrochloric Acid SCHEMBL4074918 | 0.80 | MEN1 (0.50) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2084183 | 0.78 | GRN (0.49) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL31165906 | 0.78 | ALDH1A1 (0.48) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL21436696 | 0.78 | ALDH1A1 (0.48) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10363266 | 0.78 | RAB9A (0.49) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5733233 | 0.78 | MEN1 (0.48) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL366727 | 0.77 | NPC1 (0.60) | CDK8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1690854-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7026476-B2 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7019006-B2 | Modulating release of inflammatory cytokines by administering, e.g., a 1-(5-tert-butyl-2-methyl-phenyl)-3-(6-((3-methoxy-propyl)-methylaminopyridin-3-yl)phthalen-1-yl) urea or thiourea; treating a neutrophil-mediated disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030225077-A1 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6656933-B2 | Novel compounds which inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-06-27 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225077-A1 | Intermediate arylamine compounds | AHR, AADAC, NAT1 | CDK8 928/4885MAPK14 2681/4885MAPK13 2965/4885 |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | CDK8 1006/4885MAPK14 2740/4885MAPK13 2477/4885 |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | CDK8 1006/4885MAPK14 2740/4885MAPK13 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.